Literature DB >> 24717628

Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis.

Keertan Dheda1, Tawanda Gumbo2, Neel R Gandhi3, Megan Murray4, Grant Theron5, Zarir Udwadia6, G B Migliori7, Robin Warren8.   

Abstract

Extensively drug-resistant tuberculosis is a burgeoning global health crisis mainly affecting economically active young adults, and has high mortality irrespective of HIV status. In some countries such as South Africa, drug-resistant tuberculosis represents less than 3% of all cases but consumes more than a third of the total national budget for tuberculosis, which is unsustainable and threatens to destabilise national tuberculosis programmes. However, concern about drug-resistant tuberculosis has been eclipsed by that of totally and extremely drug-resistant tuberculosis--ie, resistance to all or nearly all conventional first-line and second-line antituberculosis drugs. In this Review, we discuss the epidemiology, pathogenesis, diagnosis, management, implications for health-care workers, and ethical and medicolegal aspects of extensively drug-resistant tuberculosis and other resistant strains. Finally, we discuss the emerging problem of functionally untreatable tuberculosis, and the issues and challenges that it poses to public health and clinical practice. The emergence and growth of highly resistant strains of tuberculosis make the development of new drugs and rapid diagnostics for tuberculosis--and increased funding to strengthen global control efforts, research, and advocacy--even more pressing.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24717628      PMCID: PMC5526327          DOI: 10.1016/S2213-2600(14)70031-1

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN: 2213-2600            Impact factor:   30.700


  167 in total

1.  Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.

Authors:  Gail E Louw; Robin M Warren; Nicolaas C Gey van Pittius; Rosalba Leon; Adelina Jimenez; Rogelio Hernandez-Pando; Christopher R E McEvoy; Melanie Grobbelaar; Megan Murray; Paul D van Helden; Thomas C Victor
Journal:  Am J Respir Crit Care Med       Date:  2011-04-21       Impact factor: 21.405

2.  The competitive cost of antibiotic resistance in Mycobacterium tuberculosis.

Authors:  Sebastien Gagneux; Clara Davis Long; Peter M Small; Tran Van; Gary K Schoolnik; Brendan J M Bohannan
Journal:  Science       Date:  2006-06-30       Impact factor: 47.728

3.  Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis.

Authors:  S E Smith; E V Kurbatova; J S Cavanaugh; J P Cegielski
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

4.  Recent nosocomial transmission and genotypes of multidrug-resistant Mycobacterium tuberculosis.

Authors:  A Nodieva; I Jansone; L Broka; I Pole; G Skenders; V Baumanis
Journal:  Int J Tuberc Lung Dis       Date:  2010-04       Impact factor: 2.373

5.  Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients.

Authors:  Charlotte L Kvasnovsky; J Peter Cegielski; Roshen Erasmus; N Olga Siwisa; Khulile Thomas; Martie L van der Walt
Journal:  J Acquir Immune Defic Syndr       Date:  2011-06-01       Impact factor: 3.731

6.  Adverse events in an integrated home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa.

Authors:  James C M Brust; N Sarita Shah; Theo L van der Merwe; Sheila Bamber; Yuming Ning; Moonseong Heo; Anthony P Moll; Marian Loveday; Umesh G Lalloo; Gerald H Friedland; Neel R Gandhi
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-01       Impact factor: 3.731

7.  Comprehensive treatment of extensively drug-resistant tuberculosis.

Authors:  Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

8.  Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.

Authors:  Carole Mitnick; Jaime Bayona; Eda Palacios; Sonya Shin; Jennifer Furin; Felix Alcántara; Epifanio Sánchez; Madeleny Sarria; Mercedes Becerra; Mary C Smith Fawzi; Saidi Kapiga; Donna Neuberg; James H Maguire; Jim Yong Kim; Paul Farmer
Journal:  N Engl J Med       Date:  2003-01-09       Impact factor: 91.245

9.  Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa.

Authors:  Max R O'Donnell; N Padayatchi; I Master; G Osburn; C R Horsburgh
Journal:  Int J Tuberc Lung Dis       Date:  2009-07       Impact factor: 2.373

10.  Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa.

Authors:  Kwonjune J Seung; David B Omatayo; Salmaan Keshavjee; Jennifer J Furin; Paul E Farmer; Hind Satti
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

View more
  97 in total

1.  Molecular Epidemiological Interpretation of the Epidemic of Extensively Drug-Resistant Tuberculosis in South Africa.

Authors:  E M Streicher; S L Sampson; K Dheda; T Dolby; J A Simpson; T C Victor; N C Gey van Pittius; P D van Helden; R M Warren
Journal:  J Clin Microbiol       Date:  2015-09-02       Impact factor: 5.948

2.  High serum miR-183 level is associated with the bioactivity of macrophage derived from tuberculosis patients.

Authors:  Chunxiao Zhang; Qingjiang Wang; Xiue Xi; Junhua Jiao; Weihua Xu; Jian Huang; Zhonghai Lai
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  Impact of gyrB and eis Mutations in Improving Detection of Second-Line-Drug Resistance among Mycobacterium tuberculosis Isolates from Georgia.

Authors:  N Bablishvili; N Tukvadze; E Shashkina; B Mathema; N R Gandhi; H M Blumberg; R R Kempker
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

4.  In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China.

Authors:  Yu Pang; Zhaojing Zong; Fengmin Huo; Wei Jing; Yifeng Ma; Lingling Dong; Yunxu Li; Liping Zhao; Yuhong Fu; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

5.  The political and ethical challenge of multi-drug resistant tuberculosis.

Authors:  Chris Degeling; Christopher Mayes; Wendy Lipworth; Ian Kerridge; Ross Upshur
Journal:  J Bioeth Inq       Date:  2015-01-29       Impact factor: 1.352

6.  Epidemiology of Drug-resistant Tuberculosis in a Tertiary Care Center in Oman, 2006-2015.

Authors:  Zied Gaifer; Ahmed Babiker; Dawar Rizavi
Journal:  Oman Med J       Date:  2017-01

7.  Photoactivatable Glycolipid Probes for Identifying Mycolate-Protein Interactions in Live Mycobacteria.

Authors:  Herbert W Kavunja; Kyle J Biegas; Nicholas Banahene; Jessica A Stewart; Brent F Piligian; Jessica M Groenevelt; Caralyn E Sein; Yasu S Morita; Michael Niederweis; M Sloan Siegrist; Benjamin M Swarts
Journal:  J Am Chem Soc       Date:  2020-04-20       Impact factor: 15.419

8.  Tuberculosis screening using ability to provide sputum in an endemic emergency department.

Authors:  Eduardo Ticona; Moises A Huaman; Luz Maria Huaroto; Marcos Burgos; Meghan Brett; Rod Escombe; David A J Moore
Journal:  Eur Respir J       Date:  2015-10-22       Impact factor: 16.671

9.  The Mycobacterium tuberculosis outer membrane channel protein CpnT confers susceptibility to toxic molecules.

Authors:  Olga Danilchanka; David Pires; Elsa Anes; Michael Niederweis
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

10.  Evolution of a thienopyrimidine antitubercular relying on medicinal chemistry and metabolomics insights.

Authors:  Shao-Gang Li; Catherine Vilchèze; Sumit Chakraborty; Xin Wang; Hiyun Kim; Monica Anisetti; Sean Ekins; Kyu Y Rhee; William R Jacobs; Joel S Freundlich
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.